A multidisciplinary panel of experts has developed a set of comprehensive clinical recommendations to serve as a toolbox for managing patients with early-stage breast cancer.
Development of prognostic tool identified a range of variables that combine to predict recurrence-free and overall survival in patients with early-stage triple-negative breast cancer.
Sean McGowan, senior director of Biosimilars at AmerisourceBergen, and Brian Ansay, senior vice president of Sales and Corporate Services at ION Solutions, review 2020 biosimilar trends in oncology and forecast what is ahead in 2021.
A new online tool called RSClin was shown to estimate risk of distant recurrence and adjuvant chemotherapy benefit for patients with early breast cancer.
The pathologic complete response rate was low following salvage neoadjuvant chemotherapy for patients with neoadjuvant endocrine therapy resistant disease.
An oral chemotherapy combination delayed disease progression in patients with metastatic breast cancer, but came with added toxicity and unknown survival benefit.
Women who had a mastectomy with breast reconstruction for breast cancer treatment may be at risk for becoming dependent on opioids or sedative-hypnotic drugs.
Researchers said it was the first analysis “measuring the treatment burden of checkpoint inhibitor therapy for early-stage breast cancer using patient-reported outcomes.”
Researchers said it was the first analysis “measuring the treatment burden of checkpoint inhibitor therapy for early-stage breast cancer using patient-reported outcomes.”
